Diversified Trust Co Makes New $106,000 Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Diversified Trust Co purchased a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 12,239 shares of the biopharmaceutical company’s stock, valued at approximately $106,000.

A number of other institutional investors and hedge funds also recently modified their holdings of OCUL. SG Americas Securities LLC purchased a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at $393,000. Cetera Investment Advisers raised its holdings in shares of Ocular Therapeutix by 1.8% in the 2nd quarter. Cetera Investment Advisers now owns 739,044 shares of the biopharmaceutical company’s stock worth $5,055,000 after purchasing an additional 13,054 shares during the period. Nantahala Capital Management LLC acquired a new position in shares of Ocular Therapeutix in the 2nd quarter valued at about $6,840,000. Point72 Asset Management L.P. purchased a new stake in shares of Ocular Therapeutix during the 2nd quarter worth about $18,514,000. Finally, Second Line Capital LLC acquired a new stake in Ocular Therapeutix during the 2nd quarter worth approximately $1,798,000. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Stock Performance

Shares of OCUL stock opened at $9.78 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 16.64 and a quick ratio of 16.55. The company’s fifty day moving average price is $8.73 and its two-hundred day moving average price is $7.39. The firm has a market capitalization of $1.52 billion, a P/E ratio of -7.24 and a beta of 1.29. Ocular Therapeutix, Inc. has a 12 month low of $2.00 and a 12 month high of $11.31.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.04). Ocular Therapeutix had a negative return on equity of 52.75% and a negative net margin of 226.46%. The business had revenue of $16.40 million during the quarter, compared to analyst estimates of $15.85 million. During the same quarter last year, the firm posted ($0.27) EPS. The company’s revenue was up 7.9% compared to the same quarter last year. On average, research analysts anticipate that Ocular Therapeutix, Inc. will post -1.02 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have weighed in on OCUL shares. Piper Sandler reaffirmed an “overweight” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Friday, June 21st. HC Wainwright restated a “buy” rating and set a $14.00 target price on shares of Ocular Therapeutix in a report on Thursday, August 1st. Robert W. Baird lowered their price target on Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. Finally, TD Cowen cut Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a research note on Friday, June 21st. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.67.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.